What is CytomX Therapeutics's stock issuance proceeds?

CytomX Therapeutics (CTMX) reported stock issuance proceeds of $228.35M in Q1 2026.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

CytomX Therapeutics CTMX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Janux TherapeuticsJANX

$3.55M+293%

Allogene TherapeuticsALLO

$450K-95.5%

Design Therapeutics, Inc.DSGN

$19.91M—

ImmunomeIMNM

$229K+7.5%

Arcus BiosciencesRCUS

$0-100%

Tango TherapeuticsTNGX

$17.61M+880,150%

Other financials

Income statement

See full

Revenue$10.3M-79.9%

Operating income-$19.7M-187%

Net income-$18.2M-178%

EPS (diluted)-$0.10-137%

Balance sheet

See full

Cash & equivalents$28.8M-39.4%

Total debt$2.9M-65.0%

Total equity$319.9M+1,177%

Total assets$359.4M+265%

Cash flow

See full

Operating cash flow-$25.5M-21.4%

CapEx--100%

Free cash flow-$25.5M-20.7%

Valuation

See full

Market cap$711.89M+94.8%

Enterprise value$685.92M+110%

P/S20×+17.6×

Profitability

See full

Operating margin-181.9%-206pp

Net margin-166.4%-195pp

FCF margin-225.6%-334pp

Returns & leverage

See full

Return on equity-34.3%—

Debt / equity0×-0.3×

Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CytomX Therapeutics's stock issuance proceeds?: CytomX Therapeutics (CTMX) reported stock issuance proceeds of $228.35M in Q1 2026.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.